Why the study?
Does spironolactone exposure increase the incidence of cancer in primary care patients?
Population
74,272 patients exposed to spironolactone between 1986 and 2013, matched 1:2 with unexposed controls in UK…
Comparison
Spironolactone exposure vs Unexposed controls (1:2 propensity score-matched)
Design
Cohort
Authors
Loading...
Spironolactone was not linked to higher cancer risk and may associate with lower prostate cancer incidence; leaves open causal effects pending randomized trials.
Does spironolactone exposure increase the incidence of cancer in primary care patients?
Spironolactone use is not associated with an increased risk of incident cancers and may be associated with a lower risk of prostate cancer.
Mackenzie et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: